Using Patient Reported Outcomes (PROs) to Evaluate Teriflunomide Treatment in Relapsing Multiple Sclerosis (RMS) Patients
Public ClinicalTrials.gov record NCT01895335. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Prospective, Single-Arm, Clinical-Setting Study to Describe Efficacy, Tolerability and Convenience of Teriflunomide Treatment Using Patient Reported Outcomes (PROs) in Relapsing Multiple Sclerosis (RMS) Patients
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
Primary Objective: To describe efficacy, tolerability and convenience of teriflunomide treatment through the evaluation of Participant Reported Outcomes (PROs). Secondary Objectives: To describe disease progression using PROs. To describe clinical outcomes (ie, treated relapses) in teriflunomide treated participant. To describe the change in cognition in teriflunomide treated participants. To describe safety of teriflunomide in participant treated (based on adverse events reporting). To describe adherence and persistence to teriflunomide treatment. To describe quality of life, activity and leisure over the period of teriflunomide treatment. To compare Participant Determined Disease Steps (PDDS) and Expanded Disability Status Scale (EDSS) in assessing Multiple Sclerosis (MS) disease progression.
Study identification
- NCT ID
- NCT01895335
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 1,001 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- May 31, 2013
- Primary completion
- Oct 31, 2015
- Completion
- Oct 31, 2015
- Last update posted
- Dec 5, 2016
2013 – 2015
United States locations
- U.S. sites
- 75
- U.S. states
- 29
- U.S. cities
- 70
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Investigational Site Number 840077 | Birmingham | Alabama | 35209 | — |
| Investigational Site Number 840007 | Cullman | Alabama | — | — |
| Investigational Site Number 840087 | Phoenix | Arizona | 85004 | — |
| Investigational Site Number 840114 | Phoenix | Arizona | 85008 | — |
| Investigational Site Number 840080 | Scottsdale | Arizona | 85258 | — |
| Investigational Site Number 840032 | Tucson | Arizona | 85704 | — |
| Investigational Site Number 840021 | Phoenix | Arkansas | — | — |
| Investigational Site Number 840018 | Fullerton | California | 92835 | — |
| Investigational Site Number 840037 | Fullerton | California | 92835 | — |
| Investigational Site Number 840108 | Long Beach | California | 90806 | — |
| Investigational Site Number 840014 | Newport Beach | California | 92663 | — |
| Investigational Site Number 840019 | Oceanside | California | 92056 | — |
| Investigational Site Number 840097 | Boulder | Colorado | 80304 | — |
| Investigational Site Number 840040 | Colorado Springs | Colorado | 80907 | — |
| Investigational Site Number 840046 | Denver | Colorado | CO | — |
| Investigational Site Number 840016 | Englewood | Colorado | 80113 | — |
| Investigational Site Number 840094 | Fort Collins | Colorado | 80528 | — |
| Investigational Site Number 840024 | Bradenton | Florida | FL | — |
| Investigational Site Number 840089 | Clearwater | Florida | 33756 | — |
| Investigational Site Number 840055 | Coconut Creek | Florida | 33073 | — |
| Investigational Site Number 840104 | Hialeah | Florida | 33013 | — |
| Investigational Site Number 840101 | Miami Lakes | Florida | 33014 | — |
| Investigational Site Number 840011 | Ormond Beach | Florida | — | — |
| Investigational Site Number 840059 | Sarasota | Florida | 34239 | — |
| Investigational Site Number 840008 | St. Petersburg | Florida | — | — |
| Investigational Site Number 840081 | Sunrise | Florida | 33351 | — |
| Investigational Site Number 840002 | Atlanta | Georgia | 30318 | — |
| Investigational Site Number 840075 | Macon | Georgia | 31210 | — |
| Investigational Site Number 840012 | Fort Wayne | Indiana | — | — |
| Investigational Site Number 840010 | Indianapolis | Indiana | — | — |
| Investigational Site Number 840034 | Louisville | Kentucky | 40207 | — |
| Investigational Site Number 840047 | Rockport | Maine | 04843 | — |
| Investigational Site Number 840107 | Foxborough | Massachusetts | 02035 | — |
| Investigational Site Number 840030 | Springfield | Massachusetts | 01104 | — |
| Investigational Site Number 840073 | Clinton Township | Michigan | 48035 | — |
| Investigational Site Number 840068 | Golden Valley | Minnesota | 55422 | — |
| Investigational Site Number 840098 | Golden Valley | Minnesota | 55422 | — |
| Investigational Site Number 840086 | Chesterfield | Missouri | 63017 | — |
| Investigational Site Number 840058 | St Louis | Missouri | 63110 | — |
| Investigational Site Number 840026 | Lincoln | Nebraska | 68521 | — |
| Investigational Site Number 840020 | Henderson | Nevada | 89012 | — |
| Investigational Site Number 840049 | Freehold | New Jersey | 07728 | — |
| Investigational Site Number 840044 | Toms River | New Jersey | 08755 | — |
| Investigational Site Number 840100 | East Setauket | New York | 11733-345 | — |
| Investigational Site Number 840064 | New York | New York | 14203 | — |
| Investigational Site Number 840005 | New York | New York | — | — |
| Investigational Site Number 840071 | Schenectady | New York | 12308 | — |
| Investigational Site Number 840091 | Staten Island | New York | 10306 | — |
| Investigational Site Number 840045 | Syracuse | New York | 13202 | — |
| Investigational Site Number 840084 | Asheville | North Carolina | 28806 | — |
| Investigational Site Number 840078 | Charlotte | North Carolina | 28204 | — |
| Investigational Site Number 840042 | Raliegh | North Carolina | — | — |
| Investigational Site Number 840105 | Sanford | North Carolina | — | — |
| Investigational Site Number 840074 | Wilmington | North Carolina | 28401 | — |
| Investigational Site Number 840090 | Winston-Salem | North Carolina | 27103 | — |
| Investigational Site Number 840041 | Bismarck | North Dakota | — | — |
| Investigational Site Number 840003 | Canton | Ohio | 44718 | — |
| Investigational Site Number 840009 | Dayton | Ohio | — | — |
| Investigational Site Number 840053 | Monaca | Pennsylvania | 15061 | — |
| Investigational Site Number 840056 | Philadelphia | Pennsylvania | 19107 | — |
| Investigational Site Number 840072 | Cranston | Rhode Island | 02920 | — |
| Investigational Site Number 840048 | Nashville | Tennessee | 37215 | — |
| Investigational Site Number 840035 | Tullahoma | Tennessee | 37388 | — |
| Investigational Site Number 840060 | Dallas | Texas | 75246 | — |
| Investigational Site Number 840052 | Mansfield | Texas | 76063 | — |
| Investigational Site Number 840028 | San Antonio | Texas | 78229 | — |
| Investigational Site Number 840070 | Henrico | Virginia | 23226 | — |
| Investigational Site Number 840109 | Richmond | Virginia | 23298 | — |
| Investigational Site Number 840017 | Roanoke | Virginia | 24018 | — |
| Investigational Site Number 840054 | Vienna | Virginia | 22182 | — |
| Investigational Site Number 840069 | Spokane | Washington | 99220-3649 | — |
| Investigational Site Number 840079 | Morgantown | West Virginia | 26506-9180 | — |
| Investigational Site Number 840038 | Milwaukee | Wisconsin | 53215 | — |
| Investigational Site Number 840112 | Milwaukee | Wisconsin | — | — |
| Investigational Site Number 840076 | Neenah | Wisconsin | 54956 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 94 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT01895335, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Dec 5, 2016 · Synced Sep 4, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT01895335 live on ClinicalTrials.gov.